JPH0714905B2 - Novel method for producing 2-aminopentanoic acid compound - Google Patents
Novel method for producing 2-aminopentanoic acid compoundInfo
- Publication number
- JPH0714905B2 JPH0714905B2 JP2040393A JP4039390A JPH0714905B2 JP H0714905 B2 JPH0714905 B2 JP H0714905B2 JP 2040393 A JP2040393 A JP 2040393A JP 4039390 A JP4039390 A JP 4039390A JP H0714905 B2 JPH0714905 B2 JP H0714905B2
- Authority
- JP
- Japan
- Prior art keywords
- group
- compound
- formula
- reaction
- producing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- -1 2-aminopentanoic acid compound Chemical class 0.000 title claims description 13
- 238000004519 manufacturing process Methods 0.000 title claims description 5
- 150000001875 compounds Chemical class 0.000 claims description 14
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims description 7
- 125000003342 alkenyl group Chemical group 0.000 claims description 7
- 238000006243 chemical reaction Methods 0.000 claims description 7
- 125000000217 alkyl group Chemical group 0.000 claims description 6
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 6
- 238000006214 Clemmensen reduction reaction Methods 0.000 claims description 4
- 125000000457 gamma-lactone group Chemical group 0.000 claims description 3
- 230000006196 deacetylation Effects 0.000 claims description 2
- 238000003381 deacetylation reaction Methods 0.000 claims description 2
- 238000007142 ring opening reaction Methods 0.000 claims description 2
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 21
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 12
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 9
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 8
- ZZIKIHCNFWXKDY-GNTQXERDSA-N myriocin Chemical compound CCCCCCC(=O)CCCCCC\C=C\C[C@@H](O)[C@H](O)[C@@](N)(CO)C(O)=O ZZIKIHCNFWXKDY-GNTQXERDSA-N 0.000 description 7
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 239000003018 immunosuppressive agent Substances 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 229910052757 nitrogen Inorganic materials 0.000 description 4
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 238000002451 electron ionisation mass spectrometry Methods 0.000 description 3
- 239000010410 layer Substances 0.000 description 3
- 125000004674 methylcarbonyl group Chemical group CC(=O)* 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 125000004430 oxygen atom Chemical group O* 0.000 description 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 3
- 238000006722 reduction reaction Methods 0.000 description 3
- 229920006395 saturated elastomer Polymers 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 2
- 238000005160 1H NMR spectroscopy Methods 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- ZZIKIHCNFWXKDY-UHFFFAOYSA-N Myriocin Natural products CCCCCCC(=O)CCCCCCC=CCC(O)C(O)C(N)(CO)C(O)=O ZZIKIHCNFWXKDY-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 238000005904 alkaline hydrolysis reaction Methods 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 239000005457 ice water Substances 0.000 description 2
- 229960003444 immunosuppressant agent Drugs 0.000 description 2
- 230000001861 immunosuppressant effect Effects 0.000 description 2
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 229910052725 zinc Inorganic materials 0.000 description 2
- 239000011701 zinc Substances 0.000 description 2
- 229910000497 Amalgam Inorganic materials 0.000 description 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 241001248590 Isaria Species 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- NOMPNCQDVUXULT-UHFFFAOYSA-N acetyl acetate;hydrochloride Chemical class Cl.CC(=O)OC(C)=O NOMPNCQDVUXULT-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 235000011089 carbon dioxide Nutrition 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- RAFNCPHFRHZCPS-UHFFFAOYSA-N di(imidazol-1-yl)methanethione Chemical compound C1=CN=CN1C(=S)N1C=CN=C1 RAFNCPHFRHZCPS-UHFFFAOYSA-N 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000000921 elemental analysis Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000004992 fast atom bombardment mass spectroscopy Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000004508 fractional distillation Methods 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 1
- 150000002440 hydroxy compounds Chemical class 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 229940125721 immunosuppressive agent Drugs 0.000 description 1
- 239000012442 inert solvent Substances 0.000 description 1
- LRDFRRGEGBBSRN-UHFFFAOYSA-N isobutyronitrile Chemical compound CC(C)C#N LRDFRRGEGBBSRN-UHFFFAOYSA-N 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- GBMDVOWEEQVZKZ-UHFFFAOYSA-N methanol;hydrate Chemical compound O.OC GBMDVOWEEQVZKZ-UHFFFAOYSA-N 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 125000003553 myriocin group Chemical group 0.000 description 1
- 150000002789 myriocins Chemical class 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- DBGVGMSCBYYSLD-UHFFFAOYSA-N tributylstannane Chemical compound CCCC[SnH](CCCC)CCCC DBGVGMSCBYYSLD-UHFFFAOYSA-N 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Furan Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Description
【発明の詳細な説明】 〔産業上の利用分野〕 本発明は、医薬、特に免疫抑制剤として有用な2−アミ
ノペンタン酸化合物の新規な製造法に関する。DETAILED DESCRIPTION OF THE INVENTION [Field of Industrial Application] The present invention relates to a novel method for producing a 2-aminopentanoic acid compound useful as a medicine, particularly as an immunosuppressant.
特開平1−104087号公報には、イザリア(Isaria)属微
生物から免疫抑制物質が産生されることを、およびその
免疫抑制物質がマイリオシン(Myriocin、以下ISP−I
ともいう)であることが開示されている。このマイリオ
シン(ISP−I)とは、式 により表わされ、たとえば米国特許第3928572号明細書
により抗真菌作用を有することが知られていた。Japanese Patent Application Laid-Open No. 1-104087 discloses that an immunosuppressive substance is produced from a microorganism belonging to the genus Isaria, and that the immunosuppressive substance is myriocin (hereinafter referred to as ISP-I).
It is also disclosed). This myriocin (ISP-I) is the formula It is known to have an antifungal effect, for example from US Pat. No. 3,928,572.
ISP−Iおよび関連誘導体の免疫抑制剤については、国
際出願PCT/JP88/00933により、さらに新規な誘導体が特
願平1−176914号により特許出願されている。なかで
も、後者の特許出願ではISP−Iと同等以上の免疫抑制
活性を有する式 により表わされる化合物が開示されている。Regarding immunosuppressive agents of ISP-I and related derivatives, international application PCT / JP88 / 00933 and a novel derivative have been applied for a patent in Japanese Patent Application No. 1-176914. Among them, in the latter patent application, a formula having an immunosuppressive activity equal to or higher than that of ISP-I is used. Compounds represented by are disclosed.
前記特願平1−176914号によると、式(b)の化合物は
式(a)の化合物をピリジン中、無水酢酸で処理して得
られる窒素、酸素原子がアセチル基で保護されたγ−ラ
クトン化合物をドライアイスの存在下に水素化ホウ素ナ
トリウムによりカルボニル基を還元し、得られたヒドロ
キシ化合物に1,1′−チオカルボニルジイミダゾールを
反応させ、次いで水素化トリブチル錫および2,2′−ア
ゾ(イソブチロニトリル)にてラジカル還元し、最後に
アルカリ加水分解反応に付すことにより製造される旨、
記載されている。According to Japanese Patent Application No. 1-176914, the compound of formula (b) is a γ-lactone obtained by treating the compound of formula (a) with acetic anhydride in pyridine and having nitrogen and oxygen atoms protected by acetyl groups. The compound was subjected to reduction of the carbonyl group with sodium borohydride in the presence of dry ice, and the resulting hydroxy compound was reacted with 1,1'-thiocarbonyldiimidazole, followed by tributyltin hydride and 2,2'-azo. Radical reduction with (isobutyronitrile), and the fact that it is manufactured by finally subjecting it to an alkaline hydrolysis reaction,
Has been described.
しかしながら、当該方法は工程が長い上に、個個の工程
の収率が高くないため、より容易に式(b)の化合物を
含む5位がアルケニル基で置換された2−アミノペンタ
ン酸化合物の新規な製造法が必要であった。However, since the method has a long process and the yield of individual steps is not high, it is easier to obtain a 2-aminopentanoic acid compound containing a compound of formula (b) at the 5-position with an alkenyl group. A new manufacturing method was needed.
前記課題を解決するために、本発明者らは鋭意研究した
ところ、クレメンゼン還元反応を適用することにより容
易に目的物が得られることを見出し、本発明方法を完成
するに至った。In order to solve the above-mentioned problems, the inventors of the present invention have conducted diligent research, and have found that the target product can be easily obtained by applying the Clemmensen reduction reaction, and have completed the method of the present invention.
すなわち、本発明は一般式 (式中、R1は鎖中にカルボニル基を有するアルキル基ま
たはアルケニル基を示す。) により表わされる化合物のγ−ラクトン化合物であっ
て、アセチル基により保護された化合物をクレメンゼン
還元反応に付し、必要に応じγ−ラクトン環開裂反応お
よび/または脱アセチル基反応に付すことを特徴とする
一般式 (式中、R2はアルキル基またはアルケニル基を示す。) により表わされる2−アミノペンタン酸化合物、そのγ
−ラクトン化合物、またはアセチル基により保護された
化合物の新規な製造法に関する。That is, the present invention has the general formula (In the formula, R 1 represents an alkyl group or an alkenyl group having a carbonyl group in the chain.) A γ-lactone compound which is a compound protected by an acetyl group and subjected to a Clemmensen reduction reaction. , A general formula characterized by being subjected to a γ-lactone ring opening reaction and / or a deacetylation group reaction if necessary (In the formula, R 2 represents an alkyl group or an alkenyl group.) The 2-aminopentanoic acid compound represented by γ
-A novel method for producing a lactone compound or a compound protected by an acetyl group.
前記定義中、R1の鎖中にカルボニル基を有するアルキル
基またはアルケニル基とは (ここで、a〜jの各記号は0または1〜20の整数を示
す。) により表わされる。また、R2のアルキル基またはアルケ
ニル基としては、前記R1の例示された置換基において、
カルボニル基がメチレンに還元された基に対応する。In the above definition, the alkyl group or alkenyl group having a carbonyl group in the chain of R 1 is (Here, each symbol of a to j represents 0 or an integer of 1 to 20.). Further, as the alkyl group or alkenyl group for R 2 , in the substituents exemplified for R 1 ,
The carbonyl group corresponds to the group reduced to methylene.
本発明の目的化合物(I)においては、金属塩化合物ま
たは酸付加塩化合物、水和物またはその他の溶媒和物が
包含され、さらに、個々の光学異性体、ジアステレオ異
性体、ラセミ体も包含される。The object compound (I) of the present invention includes metal salt compounds or acid addition salt compounds, hydrates or other solvates, and further includes individual optical isomers, diastereoisomers and racemates. To be done.
本発明方法を実施するに当っては、好ましくは式(a)
で示されるISP−Iをピリジン中、無水酢酸で処理して
得られる窒素および酸素原子がアセチル基によって保護
されたγ−ラクトン化合物を出発原料とするのがよい。In carrying out the method of the present invention, preferably the formula (a)
The starting material is preferably a γ-lactone compound obtained by treating ISP-I represented by the formula (1) with acetic anhydride in pyridine and having nitrogen and oxygen atoms protected by acetyl groups.
クレメンゼン還元反応は、それ自体公知であり、反応に
不活性な溶媒(ベンゼン、トルエン、キシレン、メタノ
ール、エタノールなど)中、亜鉛末または亜鉛アマルガ
ムと塩酸とを用いて一般式(II)のγ−ラクトン化合物
であって、窒素および酸素原子がアセチル基により保護
された化合物に反応させることにより、一旦カルボニル
基がメチレン基に還元された化合物が得られる。好まし
くは塩酸の代りに塩化水素ガスを飽和させた無水酢酸を
用いるのがよい。反応は室温下または加熱下に5〜30時
間程度で進行する。The Clemmensen reduction reaction is known per se, using a powder of zinc or zinc amalgam and hydrochloric acid of the general formula (II) in an inert solvent (benzene, toluene, xylene, methanol, ethanol, etc.) for the reaction. By reacting with a lactone compound in which nitrogen and oxygen atoms are protected by an acetyl group, a compound in which a carbonyl group is once reduced to a methylene group is obtained. It is preferable to use acetic anhydride saturated with hydrogen chloride gas instead of hydrochloric acid. The reaction proceeds at room temperature or with heating for about 5 to 30 hours.
得られた化合物は、必要に応じて常法によりアルカリ加
水分解反応に付すことにより目的とする一般式(I)の
化合物が得られる。If necessary, the obtained compound is subjected to an alkaline hydrolysis reaction by a conventional method to obtain the desired compound of the general formula (I).
目的物は抽出、シリカゲルクロマト、分別蒸留、再結晶
法などにより単離精製することができる。The target product can be isolated and purified by extraction, silica gel chromatography, fractional distillation, recrystallization, etc.
本発明のように、クレメンゼン還元反応を行なうことに
より、免疫抑制剤として有用な一般式(I)の化合物が
容易に製造される。As in the present invention, the compound of the general formula (I) useful as an immunosuppressant can be easily produced by carrying out the Klemensen reduction reaction.
以下、実施例により本発明を具体的に説明するが、本発
明はこれらにより限定されるものではない。Hereinafter, the present invention will be specifically described with reference to examples, but the present invention is not limited thereto.
参考例1 ISP−I 8.10gに室温中ピリジン65mlを加え、激しく攪拌
しながら無水酢酸70mlを加えた。約1時間攪拌を続け、
ISP−Iが完全に溶けた後、攪拌を止め、一夜放置し
た。反応液に氷水を加え、酢酸エチルで抽出後、1N塩
酸、5%炭酸水素ナトリウム、飽和塩化ナトリウム水で
順次洗浄し、有機層を乾燥した。溶媒を留去して得た油
状残査10.08gを酢酸エチル:ヘキサン=7:3を展開溶媒
としてシリカゲルカラム(300g)で分離した。900〜170
0ml溶出分を合わせて減圧濃縮し、目的とするISP−I−
19.29gを無色透明油状物質として得た(収率91.4%)。Reference example 1 To 8.10 g of ISP-I, 65 ml of pyridine was added at room temperature, and 70 ml of acetic anhydride was added with vigorous stirring. Continue stirring for about 1 hour,
After ISP-I was completely dissolved, stirring was stopped and the mixture was left overnight. Ice water was added to the reaction solution, and the mixture was extracted with ethyl acetate, washed successively with 1N hydrochloric acid, 5% sodium hydrogen carbonate and saturated aqueous sodium chloride solution, and the organic layer was dried. The oily residue (10.08 g) obtained by distilling off the solvent was separated with a silica gel column (300 g) using ethyl acetate: hexane = 7: 3 as a developing solvent. 900-170
The 0 ml eluate was combined and concentrated under reduced pressure to obtain the desired ISP-I-
19.29 g was obtained as a colorless transparent oily substance (yield 91.4%).
IRνmax(CHCl3)(cm-1):2930,1760,1690,1380,12201 H‐NMR(200MHz,in CDCl3,Ref:TMS),δ:6.05(1H,b
r.s.,-NHAc),5.79(1H,d,J=4.4Hz,3-H),5.57(1H,d
t.t-like,J=15.4,6.3Hz,7-H),5.38(1H,dt.t-like,J
=15.4,6.4Hz,6-H),4.72(1H,ddd,J=7.6,5.1,4.6Hz,4
-H),4.51(2H,s,21-H2),2.5〜2.2(2H,m,5-Hz),2.38
(4H,t,J=7.5Hz,13-,15-H2),2.10(3H,s,-Ac),2.05
(3H,s,-Ac),2.03(3H,s,-Ac),2.1〜1.9(2H,m,8-
H2),1.55(4H,qui.,J=6.8Hz,12,16-H2),1.27(12H,b
r.s,9〜11,17〜19-H2),0.88(3H,t.,J=6.5Hz,20-H3)13 C‐NMR(100MHz,in CDCl3,Ref:TMS),δ:211.37(s,
14-C),172.32(s,>C=O),170.08,(s,>C=O),
169.27(s,>C=O),168.75(s,>C=O),135.04
(d,6-C),123.16(d,7-C),81.62(d,4-C),72.01(d,
3-C),62.75(t,21-C),62.73(s,2-C),42.85,42,77
(each t,13,15-C),32.46,32.20,31.63(each t,5-,8-
18−C),29.11,29.00,28.97,28.91,23.91,23.85(each
t,9〜12,16,17-C),22.76(q,-COMe),22.50(t,19-
C),20.55(q,-COMe),20.31(q,-COMe),14.00(q,20-
C) EI-MS m/z:509,491,382,348,279,129,43HREI-MS:C27H43
NO8として、計算値:509.2990、実測値:509.2998 実施例1 ISP-I-1 7.804gの塩化水素飽和‐無水酢酸液(156ml)
に、塩化ナトリウム−氷浴で冷却下、ゆっくりと攪拌し
ながら約29.5gの活性化した亜鉛末を少しずつ加えた。
添加完了後、さらに1.5時間冷却下攪拌を続けた。反応
液を綿栓濾過して、氷水中に移し、残査の亜鉛末は酢酸
エチルで洗浄した。洗浄酢酸エチル層で反応液を振盪抽
出、水層を再び酢酸エチルで抽出した。酢酸エチル層を
合わせ、飽和炭酸水素ナトリウム水溶液、飽和食塩水で
順次洗浄し、硫酸マグネシウムで乾燥後、減圧濃縮に付
し、淡黄色油状残査約7gを得た。これを直ちに酢酸エチ
ル:ヘキサン=7:3を展開溶媒としてシリカゲルカラム
(140g)で精製、分離し、ISP−I−13γ6.204gを無色
透明油状物質として得た。(収率81.7%) IRνmax(CHCl3)(cm-1):1780,1755,1685,1500,10301 ‐NMR(200MHz,in CDCl3,Ref:TMS)δ:5.99(1H,br.
s.,-NH),5.79(1H,d,J=4.4Hz,3-H),5.58(1H,dt.t-l
ike,J=15.3,6.6Hz,7-H),5.39(1H,dt,t-like,J=15.
3,7.1Hz,6-H),4.71(1H,ddd,J=7.1,5.6,4.4Hz,4-H),
4.52(2H,br.s.,21-H2),2.39(2H,m,5-H2),2.10(3H,
s,-Ac),2.05(3H,s,-Ac),2.03(3H,s,-Ac),2.01(2
H,m,8-H2),1.26(22H,br.s.,9〜19-H2),0.88(3H,t,J
=6.4Hz,20-H3)13 C‐NMR(50MHz,in CDCl3,Ref:TMS)δ:172.44(s,>
C=O),170.17(s,>C=O),169.42(s,>C=
O),168.89(s,>C=O),135,29(d,6-C),122.96
(d,7-C),81.66(d,4-C),71.93(d,3-C),62.73(t,2
1-C),62.64(s,2-C),32.57,32.18,31.91(each t,5-,
8-,18-C),29.68,29.68,29.68,29.68,29.68,29.51,29.3
6,29.21,29.21(each t,9〜17−C),22.77(q,-COM
e),22.70(t,19-C),20.58(q,-COMe),20.34(q,-COM
e),14.11(q,20-C) EI-MS m/z:495,436,376,334,265,151,129,43 HREI-MS:C27H45NO7として、計算値:495.31975、実測値:
495.31864 ISP-I-13γ 3.102gをメタノール150mlに溶かし、1N水酸
化ナトリウム水溶液37.6mlを加えて窒素気流下、一夜加
熱寒流した。反応液を1N塩酸で中和し、析出した無色物
質を吸収濾取した。ここに得た沈殿を充分に水洗し、さ
らにメタノール水(1:1)で1回洗浄し、減圧下乾燥し
てISP-I-13 2.018gを得た(収率83.2%)。融点186℃IR
νmax(KBr)(cm-1):3400,3200,1660,1565,1525,14651 H-NMR(200MHz,in CD3OD,Ref:TMS)δ:5.54(1H,dt,t-
like,J=15.4,5.9Hz,7-H),5.38(1H,dt.t-like,J=15.
4,6.1Hz,6-H),4.00(1H,d,J=11.0Hz,21-H),3.86(1
H,d,J=11.0Hz,21-H),3.83(1H,br.t.,J=7.3Hz,4-
H),3.78(1H,br.s.,3-H),2.26(2H,br.t.,J=6.8Hz,5
-H2),2.00(2H,m,8-H2),1.28(22H,br.s.,9〜19-
H2),0.90(3H,t,J=6.5Hz,20-H3) FAB-MS m/z:388,104,57,45,29 元素分析値C21H41NO5として 計算値C:65.08,H:10.66,N:3.61 実測値C:64.78,H:10.91,N:3.61IRν max (CHCl 3 ) (cm -1 ): 2930,1760,1690,1380,1220 1 H-NMR (200MHz, in CDCl 3 , Ref: TMS), δ: 6.05 (1H, b
rs, -NHAc), 5.79 (1H, d, J = 4.4Hz, 3-H), 5.57 (1H, d
tt-like, J = 15.4,6.3Hz, 7-H), 5.38 (1H, dt.t-like, J
= 15.4,6.4Hz, 6-H), 4.72 (1H, ddd, J = 7.6,5.1,4.6Hz, 4
-H), 4.51 (2H, s, 21-H 2 ), 2.5 to 2.2 (2H, m, 5-Hz), 2.38
(4H, t, J = 7.5Hz, 13-, 15-H 2 ), 2.10 (3H, s, -Ac), 2.05
(3H, s, -Ac), 2.03 (3H, s, -Ac), 2.1 to 1.9 (2H, m, 8-
H 2 ), 1.55 (4H, qui., J = 6.8Hz, 12,16-H 2 ), 1.27 (12H, b
. rs, 9~11,17~19-H 2) , 0.88 (3H, t, J = 6.5Hz, 20-H 3) 13 C-NMR (100MHz, in CDCl 3, Ref: TMS), δ: 211.37 (S,
14-C), 172.32 (s,> C = O), 170.08, (s,> C = O),
169.27 (s,> C = O), 168.75 (s,> C = O), 135.04
(D, 6-C), 123.16 (d, 7-C), 81.62 (d, 4-C), 72.01 (d,
3-C), 62.75 (t, 21-C), 62.73 (s, 2-C), 42.85,42,77
(Each t, 13,15-C), 32.46,32.20,31.63 (each t, 5-, 8-
18-C), 29.11,29.00,28.97,28.91,23.91,23.85 (each
t, 9 ~ 12,16,17-C), 22.76 (q, -COMe), 22.50 (t, 19-
C), 20.55 (q, -COMe), 20.31 (q, -COMe), 14.00 (q, 20-
C) EI-MS m / z: 509,491,382,348,279,129,43HR EI-MS: C 27 H 43
As NO 8 , calculated value: 509.2990, measured value: 509.2998 Example 1 ISP-I-1 7.804g saturated hydrogen chloride-acetic anhydride solution (156ml)
To the above, about 29.5 g of activated zinc dust was added little by little while slowly stirring with cooling with a sodium chloride-ice bath.
After the addition was completed, stirring was continued for 1.5 hours under cooling. The reaction solution was filtered with a cotton plug and transferred to ice water, and the residual zinc dust was washed with ethyl acetate. The reaction mixture was extracted with shaking using a washed ethyl acetate layer, and the aqueous layer was extracted again with ethyl acetate. The ethyl acetate layers were combined, washed successively with saturated aqueous sodium hydrogen carbonate solution and saturated brine, dried over magnesium sulfate, and concentrated under reduced pressure to give a pale yellow oily residue (about 7 g). This was immediately purified and separated on a silica gel column (140 g) using ethyl acetate: hexane = 7: 3 as a developing solvent to obtain ISP-I-13γ6.204 g as a colorless transparent oily substance. (Yield 81.7%) IRν max (CHCl 3 ) (cm −1 ): 1780,1755,1685,1500,1030 1- NMR (200MHz, in CDCl 3 , Ref: TMS) δ: 5.99 (1H, br.
s.,-NH), 5.79 (1H, d, J = 4.4Hz, 3-H), 5.58 (1H, dt.tl
ike, J = 15.3,6.6Hz, 7-H), 5.39 (1H, dt, t-like, J = 15.
3,7.1Hz, 6-H), 4.71 (1H, ddd, J = 7.1,5.6,4.4Hz, 4-H),
4.52 (2H, br.s., 21-H 2 ), 2.39 (2H, m, 5-H 2 ), 2.10 (3H,
s, -Ac), 2.05 (3H, s, -Ac), 2.03 (3H, s, -Ac), 2.01 (2
H, m, 8-H 2 ), 1.26 (22H, br.s., 9〜19-H 2 ), 0.88 (3H, t, J
= 6.4Hz, 20-H 3 ) 13 C-NMR (50MHz, in CDCl 3 , Ref: TMS) δ: 172.44 (s,>
C = O), 170.17 (s,> C = O), 169.42 (s,> C =
O), 168.89 (s,> C = O), 135,29 (d, 6-C), 122.96
(D, 7-C), 81.66 (d, 4-C), 71.93 (d, 3-C), 62.73 (t, 2
1-C), 62.64 (s, 2-C), 32.57,32.18,31.91 (each t, 5-,
8-, 18-C), 29.68,29.68,29.68,29.68,29.68,29.51,29.3
6,29.21,29.21 (each t, 9 ~ 17-C), 22.77 (q, -CO M
e ), 22.70 (t, 19-C), 20.58 (q, -CO Me ), 20.34 (q, -CO M
e ), 14.11 (q, 20-C) EI-MS m / z: 495,436,376,334,265,151,129,43 HREI-MS: C 27 H 45 NO 7 , calculated: 495.31975, found:
495.31864 3.102 g of ISP-I-13γ was dissolved in 150 ml of methanol, 37.6 ml of a 1N sodium hydroxide aqueous solution was added, and the mixture was heated and cooled overnight under a nitrogen stream. The reaction solution was neutralized with 1N hydrochloric acid, and the precipitated colorless substance was collected by absorption filtration. The precipitate obtained here was thoroughly washed with water, further washed once with methanol water (1: 1), and dried under reduced pressure to obtain 2.018 g of ISP-I-13 (yield 83.2%). Melting point 186 ℃ IR
ν max (KBr) (cm -1 ): 3400,3200,1660,1565,1525,1465 1 H-NMR (200MHz, in CD 3 OD, Ref: TMS) δ: 5.54 (1H, dt, t-
like, J = 15.4,5.9Hz, 7-H), 5.38 (1H, dt.t-like, J = 15.
4,6.1Hz, 6-H), 4.00 (1H, d, J = 11.0Hz, 21-H), 3.86 (1
H, d, J = 11.0Hz, 21-H), 3.83 (1H, br.t., J = 7.3Hz, 4-
H), 3.78 (1H, br.s., 3-H), 2.26 (2H, br.t., J = 6.8Hz, 5
-H 2 ), 2.00 (2H, m, 8-H 2 ), 1.28 (22H, br.s., 9〜19-
H 2 ), 0.90 (3H, t, J = 6.5Hz, 20-H 3 ) FAB-MS m / z: 388,104,57,45,29 Elemental analysis value C 21 H 41 NO 5 calculated value C: 65.08, H: 10.66, N: 3.61 Measured value C: 64.78, H: 10.91, N: 3.61
───────────────────────────────────────────────────── フロントページの続き (51)Int.Cl.6 識別記号 庁内整理番号 FI 技術表示箇所 C07D 307/33 ─────────────────────────────────────────────────── ─── Continuation of the front page (51) Int.Cl. 6 Identification code Internal reference number FI technical display area C07D 307/33
Claims (1)
たはアルケニル基を示す。) により表わされる化合物のγ−ラクトン化合物であっ
て、アセチル基により保護された化合物をクレメンゼン
還元反応に付し、必要に応じγ−ラクトン環開裂反応お
よび/または脱アセチル基反応に付すことを特徴とする
一般式 (式中、R2はアルキル基またはアルケニル基を示す。) により表わされる2−アミノペンタン酸化合物、そのγ
−ラクトン化合物、またはアセチル基により保護された
化合物の新規な製造法。1. A general formula (In the formula, R 1 represents an alkyl group or an alkenyl group having a carbonyl group in the chain.) A γ-lactone compound which is a compound protected by an acetyl group and subjected to a Clemmensen reduction reaction. , A general formula characterized by being subjected to a γ-lactone ring opening reaction and / or a deacetylation group reaction if necessary (In the formula, R 2 represents an alkyl group or an alkenyl group.) The 2-aminopentanoic acid compound represented by γ
-A novel method for producing lactone compounds or compounds protected by an acetyl group.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2040393A JPH0714905B2 (en) | 1990-02-20 | 1990-02-20 | Novel method for producing 2-aminopentanoic acid compound |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2040393A JPH0714905B2 (en) | 1990-02-20 | 1990-02-20 | Novel method for producing 2-aminopentanoic acid compound |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPH03246264A JPH03246264A (en) | 1991-11-01 |
| JPH0714905B2 true JPH0714905B2 (en) | 1995-02-22 |
Family
ID=12579421
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2040393A Expired - Fee Related JPH0714905B2 (en) | 1990-02-20 | 1990-02-20 | Novel method for producing 2-aminopentanoic acid compound |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPH0714905B2 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK1471054T3 (en) | 2002-01-11 | 2009-11-09 | Daiichi Sankyo Co Ltd | Amino alcohol derivative or phosphonic acid derivative and medical composition containing them |
-
1990
- 1990-02-20 JP JP2040393A patent/JPH0714905B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| JPH03246264A (en) | 1991-11-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4130566A (en) | Process for producing 5-carboxy-2-acetylthiophene | |
| USRE32518E (en) | Camptothecin derivatives | |
| JP2000500757A (en) | Epothilones C and D, methods of manufacture and compositions | |
| EP0418925B1 (en) | Method of producing (S)-4-hydroxymethyl-gamma-lactone | |
| JPH0525152A (en) | Production of 3-dpa-lactone | |
| US5284973A (en) | Method of preparing an acid additional salt of delta-aminolevulinic acid | |
| US5322955A (en) | Method of manufacturing 3-DPA-lactone | |
| CY1599A (en) | Aryltetralin derivatives | |
| JPH0714905B2 (en) | Novel method for producing 2-aminopentanoic acid compound | |
| JP2515568B2 (en) | Novel thiazolidine derivative | |
| JPH05148293A (en) | Novel capramicin derivative and method for producing the same | |
| JP2896946B2 (en) | Production method of neocardilines | |
| JPH0121146B2 (en) | ||
| NO175780B (en) | Analogous Process for the Preparation of Therapeutically Active Substituted Dibenzofurans | |
| JP3423430B2 (en) | Ascorbic acid-kojic acid conjugate and method for producing the same | |
| JP2662607B2 (en) | Bicyclo [8.3.0] trideca-9,13-diene-2,7-diyne derivative | |
| JP4690039B2 (en) | Taxane derivative functionalized at position 14 and process for its production | |
| JP2718715B2 (en) | 9,10-seco-cycloartane derivatives | |
| CH655716A5 (en) | CHIRAL CYCLOPENTENE DERIVATIVES AND PROCESSES FOR THEIR PREPARATION. | |
| JPH0522712B2 (en) | ||
| WO2001030770A1 (en) | Stereoselective synthesis of oxazoline derivative | |
| JP3231207B2 (en) | Method for producing sulfenylacetic acid derivative | |
| US4153610A (en) | Process for producing 5-carboxy-2-acetylthiophene | |
| JP3233806B2 (en) | Method for producing sulfenylacetic acid derivative | |
| JPH0533960B2 (en) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313111 |
|
| S531 | Written request for registration of change of domicile |
Free format text: JAPANESE INTERMEDIATE CODE: R313531 |
|
| R360 | Written notification for declining of transfer of rights |
Free format text: JAPANESE INTERMEDIATE CODE: R360 |
|
| R371 | Transfer withdrawn |
Free format text: JAPANESE INTERMEDIATE CODE: R371 |
|
| S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313115 |
|
| S531 | Written request for registration of change of domicile |
Free format text: JAPANESE INTERMEDIATE CODE: R313531 |
|
| R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313115 |
|
| FPAY | Renewal fee payment (prs date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20080222 Year of fee payment: 13 |
|
| R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
| LAPS | Cancellation because of no payment of annual fees |